Peregrine rises on "robust" Phase IIb second-line NSCLC data
This article was originally published in Scrip
Peregrine Pharmaceuticals shares rose by as much as 36% in early trading, and closed at $0.53, up by 20.5%, on the back of promising Phase IIb data for its first-in-class phosphatidylserine inhibitor, bavituximab. The study showed that, when used in conjunction with standard chemotherapy docetaxel, it was more active than docetaxel alone in second-line non-small cell cancer (NSCLC) – providing a doubling of objective tumour response and encouraging preliminary survival data in the study.
You may also be interested in...
ChemoCentryx has successfully completed its initial public offering on Nasdaq, raising $45 million to help support its multiple R&D programmes. It sold 4.5 million shares at $10, a somewhat less ambitious debut than it had originally planned in January when it wanted to sell four million shares at $14-$16. The reduced offer is a sign of the challenging nature of the IPO market, but ChemoCentryx's assessment of its own worth was at least closer to the market’s assessment that Cempra which got its IPO away on 6 February at valuation that was less than two-thirds of that implied by its initial prospectus (scripintelligence.com, 7 February 2012).
Ampio Pharmaceuticals, a development-stage company, initially raised $15 million which was boosted to $16.9 million by the exercise of overallotments by brokers. The shares were offered at $3.25, an 8.5% discount to the closing price of $3.66 on 12 July. The market pushed them down slightly further to 3.21 on 13 July.
Verastem, a cancer stem cells startup, has moved quickly to build its pipeline just five months after an initial public offering. Management at the Cambridge, Massachusetts firm believes that recent moves have accelerated Verastem's clinical development plans by a year.